WO1989002464A1 - Modifying living cells - Google Patents
Modifying living cells Download PDFInfo
- Publication number
- WO1989002464A1 WO1989002464A1 PCT/GB1988/000738 GB8800738W WO8902464A1 WO 1989002464 A1 WO1989002464 A1 WO 1989002464A1 GB 8800738 W GB8800738 W GB 8800738W WO 8902464 A1 WO8902464 A1 WO 8902464A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- dna
- cell
- suspension
- ultrasonic excitation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
Definitions
- This invention concerns the use of ultrasound to introduce material into, or fuse material with, living mammalian cells.
- the technique involves traumatising the cells, but not killing or disintegrating them.
- Ultrasound involves mechanical vibration at frequencies generally too high for the ear to detect, generally from 18kHz to 20MHz.
- Ultrasound has been used for diagnostic and therapeutic purposes on living mammalian tissue. The maximum intensity that can be applied without hazard has been reviewed by W.D.Ulrich (IEEE Transactions on Biomedical Engineering, January 1974, pages 48 to 51). Ultrasound is widely used to decompose or disintegrate complex chemical species, such as polymers including DNA Ultrasonic disintegraters for this purpose are commercially available. Scanning acoustic microscopes use low intensity vibrations in the MHz to GHz range.
- Electroporation involves the exposure of cells to a pulsed electric field which presumably creates pores in the plasma membrane. It has been used to introduce DNA into both plant and animal cells, and has been successfully applied to a wide range of cell types which have not been accessible to other methods (G.Chu et al. Nucleic Acids Research, Volume 15 number 3 1987, pages 1311 to 1326).
- the electrofusion technique comprises two main processes, dielectrophoresis , by which a close contact between cells is established, and electrical membrane breakdown which gives rise to small- pores in the cell membranes resulting in fusion of two apposed membranes in close contact.
- Ultrasonic forces may be used to achieve the desired close contact between cells.
- Ultrasound wavelengths may be used that are much smaller than the fusion chamber. This permits not only the production of pearl chains of cells (in a purely propagating wave) but also the concentration of cells at standing-wave pressure maxima.
- W.M.Arnold et al. (Biochemical Society Transactions, 1986, pages 246 to 249) used 1.0 MHz ultrasound (1mm wavelength) to concentrate erythrocytes or myeloma cells, for fusion by a high voltage pulse.
- the present invention provides a method of introducing material into, or fusing material with, living mammalian cells, which method comprises subjecting the cells in a vessel, in the presence of the material or immediately prior to the additon of the material, to ultrasonic excitation sufficient to traumatise the cells.
- cells in suspension are exposed to ultrasound frequencies in the KHz to MHz range. These frequencies can induce oscillations in the cells, or cavitation in the vicinity of the cells.
- the resulting stresses in the cell membranes can allow total disruption of the cell, pore formation in the celL membrane or fusion of two (or more), closely apposed cells.
- substances in the solution in which the cells are suspended may be incorporated into those cells.
- the cells are subjected to ultrasonic excitation sufficient to traumatise them. This implies that the cells are altered sufficient to effect entry of apposed material and, may be temporarily damaged, but not killed or disintegrated. Probably, pores are momentarily formed in the cell membrane, enabling apposed material to enter the cells or fuse with them. In generating sufficient ultrasound intensity to traumatise the cells, it may be unavoidable that some of them are killed.
- the nature of the mammalian cells is not critical.
- the cells are preferably maintained in suspension in aqueous or other fluid, but may alternatively be treated while adhering to a support.
- the ultrasound intensity is chosen to be • sufficient to traumatise the cells but without permanently damaging or killing them. Suitable intensities depend on a large number of factors, and are readily determined empirically for a particular experimental set-up.
- the ultrasound frequency is generally chosen in the range 18kHz to 20MHz.
- the time of treatment may be chosen empirically, but should not be so long that an unacceptable temperature rise occurs. Treatment may be continuous or in pulses. Total treatment times of a few seconds to a few minutes are likely to be appropriate.
- Materials which may be introduced into living cells by this technique include, proteins, nucleic acids, oligonucleotides, DNA, lipids and lipid vesicles. Cells which take up these materials during ultrasonic excitation can survive the process and replicate subsequently. Genes introduced into cells by this technique can be expressed and can be transmitted to daughter cells in a heritable fashion.
- materials may be incorporated by this technique into the cell membrane.
- materials for this purpose include lipids, hydrophobic proteins, membrane receptors, lipid vesicles and liposomes.
- ultrasonic excitation can be used to induce fusion of two or more apposed similar or dissimilar cells to form a single cell.
- the cells are preferably maintained in suspension in an aqueous or other liquid medium.
- Cell concentrations are generally in the range 10 4 to 108 cells/ml.
- the material is preferably present at the time of ultrasonic excitation, it may under.some circumstances be introduced during or after the excitation while the cells remain traumatised.
- the concentration of the other material should also be kept at a high " level. As discussed below, it is possible to use ultrasonic or other techniques to achieve localised high concentration, both of cells and of other material, in a suspension.
- Adjuvants may be present, including glucose/CaCl /MgCl 2 , polyethylene glycol, albumin, calmodulin, phosphatidylserine, glycerylmono-oleate, cholesterol, for cell fusion.
- the pH, salt concentration and temperature of the suspension are all factors which may affect efficiency.
- carrier DNA such as sonicated salmon sperm DNA
- the cells are held in a vessel, whose size and shape and material of construction (acoustic impedance) need to be chosen in relation to the sonicating equipment being used.
- Ultrasonic excitation may be provided by one or several ultrasonic transducers, which may be positioned above, beside or -below the vessel, or may have a probe which dips into the liquid suspension in the vessel. Or the liquid suspension may be caused to flow in a controlled manner past one or more ultrasonic transducers.
- Ultrasonic or other means may be provided for concentrating the cells at particular regions (e.g. standing waves) in the liquid suspension.
- One ultrasonic transducer may be provided to concentrate the cells, while another is operated periodically to traumatise them. Or the same transducer 'may be used for both purposes, with the power setting being periodically switched from a low level to a higher one. Control of the ultrasound frequency or frequency spectrum may be used to optimise the fusion of cells or uptake of material.
- Example 1 illustrates the invention.
- the cells were sonicated at the same settings in three separate bijou (5 x 10 cells in 5ml DMEM/bijou) for -10 seconds in the presence of 20ug pSV2 neo/EcoR1 digest and 50ug mouse carrier DNA. After sonication, the contents of each bijou were transferred to 6cm petri-dishes and cultured for two days at 37 C on standard tissue culture conditions in an atmosphere of 100% humidity, 90% air and 10% CO-. The cells were then transferred to large vessels thus
- Psi-2 fibroblasts - a retrovirus packaging line (Ref:- Cepko, C.L. et ah , Cell 3_7, 1053-1062, 1984).
- ZNR3 plasmid consisting of a cDNA encoding the human N-ras protein inserted at the Bam H1 site of the pZIP SV(X) plasmid (op. cit.)
- Mouse carrier DNA high molecular weight DNA isolated from Balb/c mouse spleens and livers and partially sheared to reduce overall molecular weight.
- DNA were included. After sonication for 10 seconds at each setting 0.2ml of cell suspension was withdrawn from each well for counting. Cell counts were as above (i.e. DNA did not alter cell viability upon sonication in this experiment).
- the remaining cells were left to attach to the bottoms of the wells in which they were contained 37°C in an atmosphere of 100% humidity, 9% C0 2 /91% air.
- the cells were transferred to 2 x 10cm tissue culture petri dishes/well, i.e. 4- petri dishes/setting of the sonicator.
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A method of introducing material into living mammalian cells, or of fusing material with the cells, comprises subjecting the cells in liquid suspension in the presence of the material to ultrasonic excitation sufficient to traumatise the cells. The material introduced into the cells, or into a cell membrane, is preferably DNA or RNA or a protein.
Description
MODIFYING LIVING CELLS
This invention concerns the use of ultrasound to introduce material into, or fuse material with, living mammalian cells. The technique involves traumatising the cells, but not killing or disintegrating them. Ultrasound involves mechanical vibration at frequencies generally too high for the ear to detect, generally from 18kHz to 20MHz.
Ultrasound has been used for diagnostic and therapeutic purposes on living mammalian tissue. The maximum intensity that can be applied without hazard has been reviewed by W.D.Ulrich (IEEE Transactions on Biomedical Engineering, January 1974, pages 48 to 51). Ultrasound is widely used to decompose or disintegrate complex chemical species, such as polymers including DNA Ultrasonic disintegraters for this purpose are commercially available. Scanning acoustic microscopes use low intensity vibrations in the MHz to GHz range.
A variety of methods of introducing material into living cells exist, including calcium phosphate precipitation and electroporation. Electroporation involves the exposure of cells to a pulsed electric field which presumably creates pores in the plasma membrane. It has been used to introduce DNA into both plant and animal cells, and has been successfully applied to a wide range of cell types which have not been accessible to other methods (G.Chu et al. Nucleic Acids Research, Volume 15 number 3 1987, pages 1311 to 1326).
Similarly, a variety of methods exists for fusing cells, including natural methods involving viruses such as Sendai or HIV, and artificial methods involving
polyethylene glycol mediated fusion or electrofusion. The electrofusion technique comprises two main processes, dielectrophoresis , by which a close contact between cells is established, and electrical membrane breakdown which gives rise to small- pores in the cell membranes resulting in fusion of two apposed membranes in close contact. (K.Ohnishi, Journal of Immunological Methods, 100 (1987) 181 to 189-
Ultrasonic forces may be used to achieve the desired close contact between cells. Ultrasound wavelengths may be used that are much smaller than the fusion chamber. This permits not only the production of pearl chains of cells (in a purely propagating wave) but also the concentration of cells at standing-wave pressure maxima. W.M.Arnold et al. (Biochemical Society Transactions, 1986, pages 246 to 249) used 1.0 MHz ultrasound (1mm wavelength) to concentrate erythrocytes or myeloma cells, for fusion by a high voltage pulse. The present invention provides a method of introducing material into, or fusing material with, living mammalian cells, which method comprises subjecting the cells in a vessel, in the presence of the material or immediately prior to the additon of the material, to ultrasonic excitation sufficient to traumatise the cells.
Briefly cells in suspension are exposed to ultrasound frequencies in the KHz to MHz range. These frequencies can induce oscillations in the cells, or cavitation in the vicinity of the cells. The resulting stresses in the cell membranes can allow total disruption of the cell, pore formation in the celL membrane or fusion of two (or more), closely apposed cells. For the duration of this cell disruption, substances in the solution in which the
cells are suspended may be incorporated into those cells.
The cells are subjected to ultrasonic excitation sufficient to traumatise them. This implies that the cells are altered sufficient to effect entry of apposed material and, may be temporarily damaged, but not killed or disintegrated. Probably, pores are momentarily formed in the cell membrane, enabling apposed material to enter the cells or fuse with them. In generating sufficient ultrasound intensity to traumatise the cells, it may be unavoidable that some of them are killed.
The nature of the mammalian cells is not critical. The cells are preferably maintained in suspension in aqueous or other fluid, but may alternatively be treated while adhering to a support.
The ultrasound intensity is chosen to be • sufficient to traumatise the cells but without permanently damaging or killing them. Suitable intensities depend on a large number of factors, and are readily determined empirically for a particular experimental set-up. The ultrasound frequency is generally chosen in the range 18kHz to 20MHz. The time of treatment may be chosen empirically, but should not be so long that an unacceptable temperature rise occurs. Treatment may be continuous or in pulses. Total treatment times of a few seconds to a few minutes are likely to be appropriate.
Materials which may be introduced into living cells by this technique include, proteins, nucleic acids, oligonucleotides, DNA, lipids and lipid vesicles. Cells which take up these materials during ultrasonic excitation can survive the process and replicate subsequently. Genes introduced into cells by this technique can be expressed and can be
transmitted to daughter cells in a heritable fashion.
Instead of being introduced into the cell interior, materials may be incorporated by this technique into the cell membrane. Examples of materials for this purpose include lipids, hydrophobic proteins, membrane receptors, lipid vesicles and liposomes. Furthermore, ultrasonic excitation can be used to induce fusion of two or more apposed similar or dissimilar cells to form a single cell.
The cells are preferably maintained in suspension in an aqueous or other liquid medium. Cell concentrations are generally in the range 10 4 to 108 cells/ml. Although the material is preferably present at the time of ultrasonic excitation, it may under.some circumstances be introduced during or after the excitation while the cells remain traumatised. w Preferably, the concentration of the other material should also be kept at a high" level. As discussed below, it is possible to use ultrasonic or other techniques to achieve localised high concentration, both of cells and of other material, in a suspension.
Various expedients, known to improve efficiency in the prior art processes of electroporation and electrofusion, are also applicable in the present invention. Adjuvants may be present, including glucose/CaCl /MgCl2, polyethylene glycol, albumin, calmodulin, phosphatidylserine, glycerylmono-oleate, cholesterol, for cell fusion. The pH, salt concentration and temperature of the suspension are all factors which may affect efficiency. For transfecting DNA into cells, the presence of carrier DNA, such as sonicated salmon sperm DNA, may increase efficiency.
The cells are held in a vessel, whose size and shape and material of construction (acoustic impedance) need to be chosen in relation to the sonicating equipment being used. Small (bijou) polystyrene _ vials or multi-well tissue culture plates are suitable. Ultrasonic excitation may be provided by one or several ultrasonic transducers, which may be positioned above, beside or -below the vessel, or may have a probe which dips into the liquid suspension in the vessel. Or the liquid suspension may be caused to flow in a controlled manner past one or more ultrasonic transducers.
Ultrasonic or other means may be provided for concentrating the cells at particular regions (e.g. standing waves) in the liquid suspension. One ultrasonic transducer may be provided to concentrate the cells, while another is operated periodically to traumatise them. Or the same transducer 'may be used for both purposes, with the power setting being periodically switched from a low level to a higher one. Control of the ultrasound frequency or frequency spectrum may be used to optimise the fusion of cells or uptake of material.
The following Examples illustrate the invention. Example 1
Equipment Soniprep 150 Ultrasonic Disintegrator - (MSE Ltd.,
Crawley) Polystyrene bijou vials 9cm tissue culture petri dishes
Cells
63.Ag8.653 mouse myeloma cells suspended in DMEM with 10% calf serum. DMEM is Dubbecco's modified eagles medium.
DNA pSV2 neo/EcoR1 digest (Southern P., and Berg P., (1982) J. Mol. Appl. Genet., Vol 1, p.327). Mouse carrier DNA: high molcular weight DNA isolated from Balb/c mouse spleens and livers and partially sheared to reduce overall molecular weight. Method
Three amplitude settings were tested for effects on cell viability. Setting Approximate % Survial after
10 second pulse
0 100
1 90 3 10
The cells were sonicated at the same settings in three separate bijou (5 x 10 cells in 5ml DMEM/bijou) for -10 seconds in the presence of 20ug pSV2 neo/EcoR1 digest and 50ug mouse carrier DNA. After sonication, the contents of each bijou were transferred to 6cm petri-dishes and cultured for two days at 37 C on standard tissue culture conditions in an atmosphere of 100% humidity, 90% air and 10% CO-. The cells were then transferred to large vessels thus
Setting 0 3 x 9cm petri-dishes
Setting 1 3 x 9cm petri-dishes
Setting 3 1 x 9cm petri-dishes
To each dish fresh DMEM + 10% calf serum was added to make the volume 10ml. The antibiotic G418 was then added to a concentration of 1mg/ml medium. The cells were then incubated for five days before being transferred to larger vessels. Inspection of the petri-dishes before this last transfer revealed
numerous surviving/replicating myeloma cells in the setting 3 dish. Fewer survivors were seen in the setting 1 dish and none were seen in the setting 0 dish. Therefore the pSV2 neo plasmid DNA had entered the sonicated myeloma cells (but not the control cells) and had integrated into those cells in a heritable fashion. This plasmid conferred resistance to the antibiotic G418 on the sonicated cells. The sonicated cells therefore survived in the antibiotic whereas the control cells, which received no plasmid did not.
After a further two weeks the cells still survived in the antibiotic, indicating that the neo gene was integrated into the cells in an heritable fashion. Example 2
Sonifection. of DNA into a Fibroblastic Cell Type
Equipment
Soniprep 150 Ultrasonic Disintegrtor - MSE
Linbro 24 well tissue culture plate - Flow Laboratories
9cm tissue culture petri-dishes - NUNC
Cells
Psi-2 fibroblasts - a retrovirus packaging line (Ref:- Cepko, C.L. et ah , Cell 3_7, 1053-1062, 1984). DNA
ZNR3 plasmid consisting of a cDNA encoding the human N-ras protein inserted at the Bam H1 site of the pZIP SV(X) plasmid (op. cit.)
Mouse carrier DNA: high molecular weight DNA isolated from Balb/c mouse spleens and livers and partially sheared to reduce overall molecular weight.
Method
Psi-2 cells were introduced into the wells of the
5 Linbro plate in suspension at 9 x 10 cells/ml medium (DMEM - Flow Laboratories with 10% donar calf bovine serum - Flow Laboratories).
As in Example 1 , the tip of the exponential microprobe of the MSE Soniprep 150 was placed in the centre of the well, in this case at a depth of 1mm below the surface of the medium. Power was applied to the microprobe for 10 seconds in each case. The effects of three different "amplitudes" (as read from the scale on the MSE apparatus) were tested on cell viability:-
Setting Viable Cells
0 8.7 x 105
1 5.4 x 105 3 1.9 x 105
For the actual experiment two wells were treated
5 at each setting. In each well, in addition to 9 x 10
"cells (initially) 10ug ZNR3 DNA and 10ug mouse-carrier
DNA were included. After sonication for 10 seconds at each setting 0.2ml of cell suspension was withdrawn from each well for counting. Cell counts were as above (i.e. DNA did not alter cell viability upon sonication in this experiment).
The remaining cells were left to attach to the bottoms of the wells in which they were contained 37°C in an atmosphere of 100% humidity, 9% C02/91% air.
After two days (sonication day 0 - cell splitting day 2) the cells were detached from the bottoms of the wells using a tryspin/EDTA solution (Flow Laboratories 2ml/we11).
The cells were transferred to 2 x 10cm tissue culture petri dishes/well, i.e. 4- petri dishes/setting of the sonicator.
9ml fresh medium were added to each petri dish which were then returned to the 37 C incubator and
incubated as before. The medium in this case, however, contains 1mg/ml G418. Cells which had taken up the plasmid ZNR3 were resistant to the antibiotic as the plasmid contained the same gene as that found in the pSV2 neo-plasmid of Example 1. Medium was changed on day 18. On day 20 the number of colonies of G418 resistant Psi-2 cells on the petri dishes (a colony was considered a group of greater than 16 cells) was counted. There results were as follows :-
Setting No. of colonies/4 petri dishes
0 0
1 207 3 0
fi
This gives an efficiency of 10 colonies/10 cells
5 surviving sonication/10ug plasmid DNA or 1/10 cells/ug. Different cell types may need different sonicator settings and different adjuvants to achieve maximum efficiency.
Claims
1. A method of introducing material into, or fusing material with, living mammalian cells, which method comprises subjecting the cells in a vessel, in the presence of the material or immediately prior to addition of the material, to ultrasonic excitation sufficient to traumatise the cells.
2. A method as claimed in claim 1 , wherein the material introduced into the cells is DNA, or RNA or protein.
3. A method as claimed in claim 2, wherein the material .introduced into the cells is a gene, and the cells are subsequently caused to replicate so that the gene is expressed and transmitted to daughter cells in a heritable manner.
4. A method as claimed in claim 1 , wherein the material is incorporated into the cell membrane.
5.. A method as claimed in claim 1 , wherein a mixture of two or more similar or dissimilar cell types is subjected to the ultrasonic excitation to induce fusion of two or more cells.
6. A method as claimed in any preceding claim, wherein the cells are maintained in suspension in a liquid.
7. A method as claimed in claim 6, wherein the cells are concentrated in suspension by means of ultrasonically induced standing waves.
8. A method as claimed in any one of claims 1 to 7, wherein, during and after ultrasonic excitation, the cells are maintained in a suitable form for reintroduction into a host mammal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB878721015A GB8721015D0 (en) | 1987-09-07 | 1987-09-07 | Modifying living cells |
GB8721015 | 1987-09-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1989002464A1 true WO1989002464A1 (en) | 1989-03-23 |
Family
ID=10623396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1988/000738 WO1989002464A1 (en) | 1987-09-07 | 1988-09-07 | Modifying living cells |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0333799A1 (en) |
JP (1) | JPH02501264A (en) |
GB (1) | GB8721015D0 (en) |
WO (1) | WO1989002464A1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991000358A1 (en) * | 1989-06-29 | 1991-01-10 | Danisco A/S | A method for introducing molecules, particularly genetic material, into plant cells |
US5612207A (en) * | 1993-03-23 | 1997-03-18 | Cbr Laboratories, Inc. | Method and apparatus for encapsulation of biologically-active substances in cells |
WO1997040679A1 (en) * | 1996-05-01 | 1997-11-06 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
US5720921A (en) * | 1995-03-10 | 1998-02-24 | Entremed, Inc. | Flow electroporation chamber and method |
WO2000008195A1 (en) * | 1998-07-31 | 2000-02-17 | Dornier Medtech Holding International Gmbh | Method and device for the transfer of oligonucleotides in cells |
US6074605A (en) * | 1995-03-10 | 2000-06-13 | Entremed, Inc. | Flow electroporation chamber and method |
WO2001048181A2 (en) * | 1999-12-23 | 2001-07-05 | Dornier Medizintechnik Gmbh | Device for transferring molecules in cells |
DE19962904A1 (en) * | 1999-12-23 | 2001-08-09 | Dornier Medizintechnik | Apparatus continuously introducing molecules into cells, avoiding their total disruption, focuses controlled acoustic pulses at axis of duct passing carrier fluid |
EP1365016A2 (en) * | 2002-05-24 | 2003-11-26 | Dornier MedTech Systems GmbH | Process abd apparatus to transfer medical actif compounds into cells |
EP1420643A2 (en) * | 2001-07-10 | 2004-05-26 | Michael N. Davidson | Enhancement of transfection of dna into the liver |
US6773669B1 (en) | 1995-03-10 | 2004-08-10 | Maxcyte, Inc. | Flow electroporation chamber and method |
US7029916B2 (en) | 2001-02-21 | 2006-04-18 | Maxcyte, Inc. | Apparatus and method for flow electroporation of biological samples |
US7141425B2 (en) | 2001-08-22 | 2006-11-28 | Maxcyte, Inc. | Apparatus and method for electroporation of biological samples |
US7771984B2 (en) | 2004-05-12 | 2010-08-10 | Maxcyte, Inc. | Methods and devices related to a regulated flow electroporation chamber |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3505161A1 (en) * | 1985-02-15 | 1986-08-21 | GCA Corp., Bedford, Mass. | Process and apparatus for electrofusion with the aid of sound waves |
-
1987
- 1987-09-07 GB GB878721015A patent/GB8721015D0/en active Pending
-
1988
- 1988-09-07 EP EP88907755A patent/EP0333799A1/en not_active Withdrawn
- 1988-09-07 JP JP63507367A patent/JPH02501264A/en active Pending
- 1988-09-07 WO PCT/GB1988/000738 patent/WO1989002464A1/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3505161A1 (en) * | 1985-02-15 | 1986-08-21 | GCA Corp., Bedford, Mass. | Process and apparatus for electrofusion with the aid of sound waves |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU645260B2 (en) * | 1989-06-29 | 1994-01-13 | Sandoz Ltd. | A method for introducing molecules, particularly genetic material, into plant cells |
WO1991000358A1 (en) * | 1989-06-29 | 1991-01-10 | Danisco A/S | A method for introducing molecules, particularly genetic material, into plant cells |
US5612207A (en) * | 1993-03-23 | 1997-03-18 | Cbr Laboratories, Inc. | Method and apparatus for encapsulation of biologically-active substances in cells |
US6773669B1 (en) | 1995-03-10 | 2004-08-10 | Maxcyte, Inc. | Flow electroporation chamber and method |
US5720921A (en) * | 1995-03-10 | 1998-02-24 | Entremed, Inc. | Flow electroporation chamber and method |
US6074605A (en) * | 1995-03-10 | 2000-06-13 | Entremed, Inc. | Flow electroporation chamber and method |
WO1997040679A1 (en) * | 1996-05-01 | 1997-11-06 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
WO2000008195A1 (en) * | 1998-07-31 | 2000-02-17 | Dornier Medtech Holding International Gmbh | Method and device for the transfer of oligonucleotides in cells |
WO2001048181A2 (en) * | 1999-12-23 | 2001-07-05 | Dornier Medizintechnik Gmbh | Device for transferring molecules in cells |
DE19962904A1 (en) * | 1999-12-23 | 2001-08-09 | Dornier Medizintechnik | Apparatus continuously introducing molecules into cells, avoiding their total disruption, focuses controlled acoustic pulses at axis of duct passing carrier fluid |
WO2001048181A3 (en) * | 1999-12-23 | 2002-04-18 | Dornier Medizintechnik | Device for transferring molecules in cells |
US7029916B2 (en) | 2001-02-21 | 2006-04-18 | Maxcyte, Inc. | Apparatus and method for flow electroporation of biological samples |
EP1420643A2 (en) * | 2001-07-10 | 2004-05-26 | Michael N. Davidson | Enhancement of transfection of dna into the liver |
EP1420643A4 (en) * | 2001-07-10 | 2005-01-05 | Michael N Davidson | Enhancement of transfection of dna into the liver |
US7211248B2 (en) | 2001-07-10 | 2007-05-01 | Sonogene, L.L.C. | Enhancement of transfection of DNA into the liver |
US7141425B2 (en) | 2001-08-22 | 2006-11-28 | Maxcyte, Inc. | Apparatus and method for electroporation of biological samples |
US7186559B2 (en) | 2001-08-22 | 2007-03-06 | Maxcyte, Inc. | Apparatus and method for electroporation of biological samples |
EP1365016A3 (en) * | 2002-05-24 | 2004-01-21 | Dornier MedTech Systems GmbH | Process abd apparatus to transfer medical actif compounds into cells |
EP1365016A2 (en) * | 2002-05-24 | 2003-11-26 | Dornier MedTech Systems GmbH | Process abd apparatus to transfer medical actif compounds into cells |
US7771984B2 (en) | 2004-05-12 | 2010-08-10 | Maxcyte, Inc. | Methods and devices related to a regulated flow electroporation chamber |
US9546350B2 (en) | 2004-05-12 | 2017-01-17 | Maxcyte, Inc. | Methods and devices related to a regulated flow electroporation chamber |
Also Published As
Publication number | Publication date |
---|---|
EP0333799A1 (en) | 1989-09-27 |
JPH02501264A (en) | 1990-05-10 |
GB8721015D0 (en) | 1987-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU645260B2 (en) | A method for introducing molecules, particularly genetic material, into plant cells | |
WO1989002464A1 (en) | Modifying living cells | |
US6627421B1 (en) | Methods and systems for applying multi-mode energy to biological samples | |
JP2739978B2 (en) | Method and apparatus for cell poration and cell fusion by high frequency electrical pulses | |
CA1338931C (en) | Multiplying bovine embryos | |
Kubiak et al. | Electrofusion of mouse blastomeres | |
EP0710718B1 (en) | Apparatus for cell poration and cell fusion using radiofrequency electrical pulses | |
Greenleaf et al. | Artificial cavitation nuclei significantly enhance acoustically induced cell transfection | |
JP7155318B2 (en) | High-efficiency transfection of biological cells using sonoporation | |
EP0386086B1 (en) | Method for cell poration and cell fusion using radiofrequency electrical pulses | |
Zerbib et al. | Electric field mediated transformation: isolation and characterization of a TK+ subclone | |
JP2011147399A (en) | Foreign gene transfer method by electroporation method | |
Xie et al. | Study of mechanisms of electric field-induced DNA transfection. II. Transfection by low-amplitude, low-frequency alternating electric fields | |
Winterbourne et al. | Electric shock-mediated transfection of cells. Characterization and optimization of electrical parameters | |
EP1054959B1 (en) | High efficiency methods and compositions for integrating exogenous dna into genomic dna of sperm | |
Anderson et al. | Electroporation of lymphoid cells: factors affecting the efficiency of transfection | |
Kono et al. | Effects of induction current and other factors on large‐scale electrofusion for pronuclear transplantation of mouse eggs | |
Kurischko et al. | 883—Electrofusion of rat and mouse blastomeres | |
Miyoshi et al. | In vitro development of cloned embryos derived from miniature pig somatic cells after activation by ultrasound stimulation | |
Fuhr et al. | Electrorotation of oat protoplasts before and after fusion | |
Satyabhama et al. | Short-term efficient expression of transfected DNA in human hematopoietic cells by electroporation: definition of parameters and use of chemical stimulators | |
Roseboro et al. | Effect of ultrasonic irradiation on mammalian cells and chromosomes in vitro | |
Hibi | Plant protoplast fusion by electromanipulation | |
CA1340200C (en) | Method of and apparatus for cell poration and cell fusion using radiofrequency electrical pulses | |
Berg | Electromagnetic field effects on cell membranes and cell metabolism |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1988907755 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1988907755 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1988907755 Country of ref document: EP |